Takeda To Acquire Late-Stage, Potential Best-In-Class, Oral Allosteric Tyk2 Inhibitor Ndi-034858 From Nimbus Therapeutics
Takeda To Acquire Late-Stage, Potential Best-In-Class, Oral Allosteric Tyk2 Inhibitor Ndi-034858 From Nimbus Therapeutics
12/13/22, 12:02 PM
Location
tokyoTakeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279.
Company Info
Location
Tokyo, Tokyo, Japan
Company info
Takeda Pharmaceuticals is Japan's largest drugmaker. It has transformed into one of the world's leading pharmaceutical companies under CEO Christophe Weber. The company operates in approximately 80 countries and focuses on high-impact therapeutic areas. Takeda is committed to scaling innovation capabilities and shaping the future of global healthcare.